7 results
Systemic Lupus Erythematosus (SLE) - Diagnosis and Management Summary
 • Epidemiology: 10-180/100,000, Typically Age 20-40, F:M
Systemic Lupus Erythematosus ... 40, F:M 9:1 • Clinical ... Manifestations: Malar rash ... life-threatening • Treatment ... #Summary #rheumatology
CNS Manifestations of Systemic Lupus Erythematosus (SLE)

Clinical Manifestations: Demyelinating Syndrome, Headache, Movement disorders, Seizure disorders, Aseptic
(SLE) Clinical ... autoantibodies that will cause ... thrombosis and/or blood-brain ... #rheumatology # ... cerebritis #diagnosis #management
Drug Induced Lupus vs SLE
Drug Induced Lupus (DIL):
 • Epidemiology: -10% of all lupus cases, drug-dependent,
to 1:1 F:M • Clinical ... NPSLE rare, Malar rash ... Discontinuation of causal ... Systemic Lupus Erythematosus ... comparison #table #rheumatology
Macrophage Activation Syndrome (MAS)
Classified among the secondary or acquired forms of haemophagocytic lymphohistiocytosis (sHLH)

What?
A subset of
Petechial or purpuric rash ... [SLE], AOSD) • ... Treatment: • Corticosteroids ... Syndrome #Diagnosis #Management ... #Hematology #Rheumatology
Hemophagocytic Lymphohistiocytosis (HLH)
Pathophysiology: Triggering factor (infection,...)→Activation of CD8 T cells (IFN-y) → Excessive activation of macrophages
Phagocytosis of blood ... Autoimmune diseases: SLE ... Treatment: • ... Lymphohistiocytosis #diagnosis #management ... #rheumatology
Drug Induced Lupus (DIL)
 • Epidemiology: -10% of all lupus cases, drug-dependent, 4:1 to 1:1 F:M
to 1:1 F:M • Clinical ... NPSLE rare, Malar rash ... is rare in DIL, SCLE-DIL ... DrugInduced #Lupus #DIL #rheumatology ... #management
Anti-NXP-2 Dermatomyositis

What?
DM with generalized subcutaneous edema
Pts have more myalgias, more severe weakness, and an increased prevalence
auricular papules Clinical ... Muscle atrophy may cause ... positive patients Treatment ... Dermatomyositis #diagnosis #management ... #rheumatology #